RNF213 Variants and Collateral Vessels in Moyamoya Disease

Overview

The purpose of this study is to detect the association between RNF213 variants and collateral vessels in patients with moyamoya disease.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 30, 2021

Detailed Description

Moyamoya disease (MMD) is a chronic cerebrovascular disorder characterized by the presence of occlusion which occurs at the internal carotid arteries and their main branches during the development of a basal collateral network. The ring finger 213 (RNF213) was identified as a strong susceptibility gene in patients with MMD in East Asia. The role of RNF213 variants in pathogenesis of MMD is still unclear. Specific "moyamoya vessels" correlate with the onset of stroke. The purpose of this study is to investigate the relationship between RNF213 variants and collateral vessels in patients with moyamoya disease, and provide potential pathogenesis of moyamoya disease.

Interventions

  • Other: Identification of genetic variants
    • Identification of genetic variants

Arms, Groups and Cohorts

  • Moyamoya disease patients
    • Moyamoya disease patients’ inclusion Criteria: 1. Written informed consent is obtained; 2. Patients with age between 4-60 years; 3. Cerebral digital subtraction contrast angiography (DSA) reveal severe stenosis or occlusion of the distal internal carotid or proximal middle and anterior cerebral arteries with prominent lenticulostriate ‘moyamoya collaterals’. Exclusion Criteria: 1. There are other vascular diseases, including systemic vasculitis, neurofibroma, meningitis, sickle cell disease, down’s syndrome, and previous basilar radiotherapy; 2. Patients with cardiogenic embolism, including a history of atrial fibrillation, valvular disease or cardiac valve replacement; 3. Physical or subjective failure to cooperate with the examination or serious comorbid diseases.

Clinical Trial Outcome Measures

Primary Measures

  • Identification of RNF213 variants and different types of collateral vessels
    • Time Frame: Baseline

Secondary Measures

  • Identification of serum biomarkers and different types of collateral vessels
    • Time Frame: Baseline
    • Hcy, HDL, LDL, ApoA, ApoB et al.
  • Identification of clinical characteristics and different types of collateral vessels
    • Time Frame: Baseline
    • Age, Gender, Clinical manifestations, Comorbidities, BMI et al.
  • Identification of RNF213 variants, serum biomarkers, clinical characteristics and different types of postoperative collateral vessels
    • Time Frame: 6-12 months

Participating in This Clinical Trial

Inclusion Criteria

  • Written informed consent is obtained – Patients with age between 4-60 years – Cerebral digital subtraction contrast angiography (DSA) reveal severe stenosis or occlusion of the distal internal carotid or proximal middle and anterior cerebral arteries with prominent lenticulostriate 'moyamoya collaterals' Exclusion Criteria:

  • There are other vascular diseases, including systemic vasculitis, neurofibroma, meningitis, sickle cell disease, down's syndrome, and previous basilar radiotherapy – Patients with cardiogenic embolism, including a history of atrial fibrillation, valvular disease or cardiac valve replacement – Physical or subjective failure to cooperate with the examination or serious comorbid diseases

Gender Eligibility: All

Minimum Age: 4 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Beijing Tiantan Hospital
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.